Clinical Trials

Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06034470 2026-04-14

Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms

30 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT02381886 2026-04-13

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

CNSGastrointestinalMyeloidOther hematologic neoplasm

166 enrolled

Astrocytoma, Glioblastoma, Glioma, Leukemia, Myelodysplastic Syndromes, Oligodendroglioma, Leukemia, Myeloid, Acute, Cholangiocarcinoma

NCT03017820 2026-04-13

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cell

127 enrolled

Immunoblastic Lymphadenopathy, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic

NCT03816319 2026-04-13

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

Classical hematologyMyeloidOther hematologic neoplasm

42 enrolled

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06047886 2026-04-13

UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy

50 enrolled

Myelodysplastic Syndromes, Hematologic Neoplasms, Primary Myelofibrosis

NCT06146257 2026-04-13

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

48 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06484062 2026-04-13

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

54 enrolled

GATA2 Deficiency, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06656494 2026-04-13

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

266 enrolled

Phase 1 Enrolling by invitation

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06788509 2026-04-13

A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring

120 enrolled

GenitourinaryLymphoidMyeloidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Prostatic Neoplasms, Castration-Resistant

NCT06888323 2026-04-13

Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment

Phase 1 Suspended

30 enrolled

Myeloid

Myelodysplastic Syndromes

NCT06021600 2026-04-09

A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine

3 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05088356 2026-04-08

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

77 enrolled

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05473910 2026-04-08

A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation

75 enrolled

Myelodysplastic Syndromes, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06419634 2026-04-08

Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

105 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04227847 2026-04-07

A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies

178 enrolled

Phase 1 Not yet recruiting

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07254793 2026-04-07

Prophylactic and Therapeutic DLI-X for Leukemia Relapse After HCT

94 enrolled

Lymphoma, Non-Hodgkin, Motor Activity, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05263271 2026-04-06

Gentulizumab in Relapsed/Refractory Acute Myelogenous Leukemia or Myelodysplastic Syndrome

58 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04024761 2026-04-03

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

50 enrolled

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Juvenile

NCT04279847 2026-04-01

LIMBER

140 enrolled

Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, Recurrence, Thrombocythemia, Essential, Primary Myelofibrosis

NCT04980404 2026-03-30

Inqovi Maintenance Therapy in Myeloid Neoplasms

22 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myelomonocytic, Chronic

NCT05933070 2026-03-30

LAUREL

2 enrolled

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute

NCT05552469 2026-03-27

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

62 enrolled

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT07020533 2026-03-27

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

46 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

29 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03533816 2026-03-25

Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide

38 enrolled

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07107126 2026-03-25

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

24 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03494569 2026-03-18

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Phase 1 Suspended

36 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05275439 2026-03-18

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

106 enrolled 28 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05636514 2026-03-18

CELESTIAL-MDS

12 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07270978 2026-03-13

AML-MDS 001

23 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT03232268 2026-03-12

MICROSTEM

Phase 1 Completed

25 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

30 enrolled

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04953897 2026-03-10

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

18 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04953910 2026-03-10

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

27 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03969446 2026-03-05

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

54 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04375631 2026-03-05

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

120 enrolled

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06498973 2026-03-05

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

43 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06543381 2026-03-05

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

15 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT07044544 2026-03-04

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

20 enrolled

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT03772925 2026-03-03

Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

18 enrolled 19 charts

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06846606 2026-03-03

Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS

34 enrolled

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT07283094 2026-03-03

FHD-286

33 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03630991 2026-03-02

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

58 enrolled

Classical hematologyMyeloidOther hematologic neoplasm

Blast Crisis, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases

NCT03358719 2026-02-27

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Phase 1 Completed

8 enrolled 9 charts

Anemia, Refractory, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT05170828 2026-02-24

Cryopreserved MMUD BM With PTCy for Hematologic Malignancies

Phase 1 Withdrawn